$SKYE
Skye Bioscience, Inc. Stock $skye

$skye Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000151655124000048 Filed on March 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.206M	$2.495M	$7.852M
YoY Change	119.59%	61.95%	28.84%
% of Gross Profit
Research & Development	$1.946M	$1.591M	$5.819M
YoY Change	64.27%	3.53%	-3.2%
% of Gross Profit
Depreciation & Amortization	$27.56K	$24.25K	$124.3K
YoY Change	-16.92%	-23.09%	8.05%
% of Gross Profit
Operating Expenses	$6.152M	$4.086M	$34.74M
YoY Change	98.45%	32.77%	89.69%
Operating Profit	-$6.152M		-$34.74M
YoY Change	98.45%		89.69%
Interest Expense	$436.9K	-$379.8K	$906.3K
YoY Change	2274.78%	152.45%	36.25%
% of Operating Profit
Other Income/Expense, Net	$1.135M	$0.00	-$2.906M
YoY Change	-154.89%	-100.0%	149.84%
Pretax Income	-$5.018M	-$4.420M	-$37.64M
YoY Change	-2.9%	-55.31%	93.28%
Income Tax	$2.000K	$0.00	$3.600K
% Of Pretax Income
Net Earnings	-$5.020M	-$4.420M	-$37.64M
YoY Change	-2.86%	-55.32%	93.23%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.18		-$5.37
Diluted Earnings Per Share	-$0.18	-$0.36	-$5.37
COMMON SHARES
Basic Shares Outstanding	28.06M shares	12.34M shares	7.006M shares
Diluted Shares Outstanding	28.00M shares		7.006M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.16M	$1.429M	$1.429M
YoY Change	3053.49%	14.81%	14.81%
Cash & Equivalents	$83.34M	$10.34M	$1.256M
Short-Term Investments
Other Short-Term Assets	$1.506M	$888.9K	$10.19M
YoY Change	83.71%	115.75%	32.34%
Inventory
Prepaid Expenses	$640.5K	$425.3K
Receivables
Other Receivables
Total Short-Term Assets	$94.57M	$11.65M	$11.65M
YoY Change	2024.75%	30.27%	30.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$36.08K	$43.28K	$281.3K
YoY Change	-53.2%	-50.74%	76.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.309K	$8.309K	$8.310K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$265.2K	$289.6K	$289.6K
YoY Change	94.93%	73.03%	73.03%
TOTAL ASSETS
Total Short-Term Assets	$94.57M	$11.65M	$11.65M
Total Long-Term Assets	$265.2K	$289.6K	$289.6K
Total Assets	$94.84M	$11.94M	$11.94M
YoY Change	1967.51%	31.05%	31.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.095M	$1.156M	$1.156M
YoY Change	-10.54%	-30.79%	-35.61%
Accrued Expenses	$3.795M	$2.069M	$2.069M
YoY Change	229.05%	175.09%	4.29%
Deferred Revenue
YoY Change
Short-Term Debt	$4.609M	$4.372M	$4.372M
YoY Change			7784.58%
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$15.80M	$13.90M	$13.90M
YoY Change	68.68%	14.7%	14.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$151.0K	$171.2K	$171.2K
YoY Change
Total Long-Term Liabilities	$151.0K	$171.2K	$171.2K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.80M	$13.90M	$13.90M
Total Long-Term Liabilities	$151.0K	$171.2K	$171.2K
Total Liabilities	$15.95M	$14.07M	$14.07M
YoY Change	70.29%	16.12%	16.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$109.4M	-$104.4M
YoY Change	52.15%	56.41%
Common Stock	$188.3M	$102.3M
YoY Change	180.5%	60.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$78.88M	-$2.132M	-$2.132M
YoY Change
Total Liabilities & Shareholders Equity	$94.84M	$11.94M	$11.94M
YoY Change	1967.51%	31.05%	31.05%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$5.020M	-$4.420M	-$37.64M
YoY Change	-2.86%	-55.32%	93.23%
Depreciation, Depletion And Amortization	$27.56K	$24.25K	$124.3K
YoY Change	-16.92%	-23.09%	8.05%
Cash From Operating Activities	-$4.708M	-$3.842M	-$13.95M
YoY Change	15.94%	-21.13%	9.48%
INVESTING ACTIVITIES
Capital Expenditures	$3.181K	$2.550K	$12.55K
YoY Change	71.02%	-100.71%	-55.27%
Acquisitions
YoY Change
Other Investing Activities	$1.145M	-$990.00	$6.609M
YoY Change	-79.3%	-100.02%	24.49%
Cash From Investing Activities	$1.142M	-$3.540K	$6.596M
YoY Change	-79.35%	-100.06%	26.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$4.974M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$85.65M	-26.73K	$16.44M
YoY Change	-189149.41%	-178.23%	-7975.36%
NET CHANGE
Cash From Operating Activities	-$4.708M	-3.842M	-$13.95M
Cash From Investing Activities	$1.142M	-3.540K	$6.596M
Cash From Financing Activities	$85.65M	-26.73K	$16.44M
Net Change In Cash	$82.09M	-3.872M	$9.088M
YoY Change	5663.79%	-567.03%	-217.43%
FREE CASH FLOW
Cash From Operating Activities	-$4.708M	-$3.842M	-$13.95M
Capital Expenditures	$3.181K	$2.550K	$12.55K
Free Cash Flow	-$4.711M	-$3.845M	-$13.96M
YoY Change	15.96%	-14.83%	9.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55136
CY2023	dei	Entity Registrant Name EntityRegistrantName	Skye Bioscience, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0692882
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	11250 El Camino Real
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	410-0266
CY2023Q4	us-gaap	Cash Cash	1256453	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9080202	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	425259	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	6432216	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	481588	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	8943718	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	87854	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	71191	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8309	usd
CY2022Q4	us-gaap	Assets Assets	9111072	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2906011	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1163129	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37641184	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19474861	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3600	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6741	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37644784	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19481602	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.37
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.77
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.37
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7006038	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2221080	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7006038	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2221080	shares
CY2023	skye	Finance Charge From Sciences Warrant Repricing FinanceChargeFromSciencesWarrantRepricing	0	usd
CY2022	skye	Finance Charge From Sciences Warrant Repricing FinanceChargeFromSciencesWarrantRepricing	120228	usd
CY2023	us-gaap	Depreciation Depreciation	124251	usd
CY2022	us-gaap	Depreciation Depreciation	114998	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	97986	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001516551
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28062907	shares
CY2023	us-gaap	Operating Expenses OperatingExpenses	34735173	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	18311732	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-34735173	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18311732	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	102857	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	987510	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28062907	shares
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.004
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.004
CY2021Q4	us-gaap	Derivative Liability Current Statement Of Financial Position Extensible Enumeration DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Derivative Liability Current Statement Of Financial Position Extensible Enumeration DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	20402540	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104382549	usd
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	East Hanover, New Jersey
CY2022Q4	us-gaap	Cash Cash	1244527	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4580	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	780807	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	888929	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	11650843	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43276	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	237983	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8309	usd
CY2023Q4	us-gaap	Assets Assets	11940411	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	888381	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	657734	usd
CY2023Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	6053468	usd
CY2022Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	6205310	usd
CY2023Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1848375	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	4371998	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	72038	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	78700	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13900999	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12119126	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	171230	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14072229	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12119126	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12349243	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12349243	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3654119	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3654119	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12349	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3654	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	102238382	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	63726057	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104382549	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66737765	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2131818	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3008054	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11940411	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9111072	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5819461	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6011805	usd
CY2023	skye	In Process Research And Development InProcessResearchAndDevelopment	21215214	usd
CY2022	skye	In Process Research And Development InProcessResearchAndDevelopment	0	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7852340	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6094617	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	151842	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-6205310	usd
CY2023	skye	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-3	usd
CY2022	skye	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-59729	usd
CY2023	us-gaap	Interest Expense InterestExpense	906270	usd
CY2022	us-gaap	Interest Expense InterestExpense	665133	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	19011	usd
CY2023	skye	Finance Charge FinanceCharge	0	usd
CY2022	skye	Finance Charge FinanceCharge	120228	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-307086	usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.77
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	4080	usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	987510	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	629032	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-59729	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	329890	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	489595	usd
CY2023	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	-151843	usd
CY2022	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	6205310	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-307086	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1383285	usd
CY2022	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0	usd
CY2023	skye	Accrued Interest Conversion Expense AccruedInterestConversionExpense	15952	usd
CY2022	skye	Accrued Interest Conversion Expense AccruedInterestConversionExpense	0	usd
CY2023	skye	In Process Research And Development InProcessResearchAndDevelopment	21215214	usd
CY2022	skye	In Process Research And Development InProcessResearchAndDevelopment	0	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	45350	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-564232	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	16396	usd
CY2023	skye	Increase Decrease In Prepaid Expenses Due From Related Parties IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties	0	usd
CY2022	skye	Increase Decrease In Prepaid Expenses Due From Related Parties IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties	-13432	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	257790	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-112907	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-576384	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	688269	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-124901	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	111471	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	230647	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	313284	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-493471	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1839252	usd
CY2023	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-95850	usd
CY2022	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	95850	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-76566	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-82372	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13952178	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12744072	usd
CY2023	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	5532266	usd
CY2022	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	-66458	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12550	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28060	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	0	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	1475144	usd
CY2023	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1076740	usd
CY2022	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	5308913	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6596456	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5214395	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	265053	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4973684	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	6026	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	259335	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	275537	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	680901	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	616125	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-208794	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7738471	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1249107	usd
CY2023Q4	us-gaap	Cash Cash	1256453	usd
CY2022Q4	us-gaap	Cash Cash	1244527	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	4580	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1249107	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	198352	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	333547	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	3600	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	6741	usd
CY2023	skye	Financing Of Insurance Premium FinancingOfInsurancePremium	203884	usd
CY2023	skye	Common Stock Warrant Exercises CommonStockWarrantExercises	282906	usd
CY2022	skye	Common Stock Warrant Exercises CommonStockWarrantExercises	0	usd
CY2023	skye	Conversion Of Multi Draw Credit Agreement ConversionOfMultiDrawCreditAgreement	1565470	usd
CY2022	skye	Conversion Of Multi Draw Credit Agreement ConversionOfMultiDrawCreditAgreement	0	usd
CY2023	skye	Conversion Of Accrued Interest Due To Related Party ConversionOfAccruedInterestDueToRelatedParty	31766	usd
CY2022	skye	Conversion Of Accrued Interest Due To Related Party ConversionOfAccruedInterestDueToRelatedParty	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	241134	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	skye	Stock Issued For Assets Net Of Equity Issuance Costs StockIssuedForAssetsNetOfEquityIssuanceCosts	20532846	usd
CY2023	skye	Deferred Issuance Costs DeferredIssuanceCosts	0	usd
CY2022	skye	Deferred Issuance Costs DeferredIssuanceCosts	22471	usd
CY2023	skye	Purchases Of Property And Equipment In Other Current Liabilities PurchasesOfPropertyAndEquipmentInOtherCurrentLiabilities	0	usd
CY2022	skye	Purchases Of Property And Equipment In Other Current Liabilities PurchasesOfPropertyAndEquipmentInOtherCurrentLiabilities	11300	usd
CY2023	skye	Release Of Share Liability To Additional Paid In Capital ReleaseOfShareLiabilityToAdditionalPaidInCapital	0	usd
CY2022	skye	Release Of Share Liability To Additional Paid In Capital ReleaseOfShareLiabilityToAdditionalPaidInCapital	13000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022	skye	Stock Issued For Assets Net Of Equity Issuance Costs StockIssuedForAssetsNetOfEquityIssuanceCosts	3074098	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	5864166	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	629032	usd
CY2022	skye	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	1967	usd
CY2022	skye	Payments Of Stock Issuance Costs Other PaymentsOfStockIssuanceCostsOther	25511	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9858155	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	120228	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19481602	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3008054	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2980521	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	21609586	usd
CY2023Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	265053	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11734947	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	925550	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37644784	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2131818	usd
CY2023Q4	skye	Working Capital Earnings Deficit WorkingCapitalEarningsDeficit	-2250156	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104382549	usd
CY2023Q4	us-gaap	Cash Cash	1256453	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-34735173	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-18311732	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19481602	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	26349	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates and judgements used in determining stock based compensation expense and estimates related to the Company's estimation of the percentage of completion under its research and development contracts, which are not readily apparent from other sources.</span></div>
CY2023	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	61767	usd
CY2022	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	63717	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized After Tax ForeignCurrencyTransactionGainLossRealizedAfterTax	-9143	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized After Tax ForeignCurrencyTransactionGainLossRealizedAfterTax	-3352	usd
CY2023Q3	skye	Asset Acquisition Share Price AssetAcquisitionSharePrice	3.975
CY2023Q4	skye	Prepaid Clinical Expenses PrepaidClinicalExpenses	292352	usd
CY2022Q4	skye	Prepaid Clinical Expenses PrepaidClinicalExpenses	646072	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	132907	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	134735	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	425259	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	780807	usd
CY2023Q4	skye	Tax Rebate Current TaxRebateCurrent	540604	usd
CY2022Q4	skye	Tax Rebate Current TaxRebateCurrent	179687	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	172439	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	101386	usd
CY2023Q4	skye	Excise Tax Bonds Current ExciseTaxBondsCurrent	125784	usd
CY2022Q4	skye	Excise Tax Bonds Current ExciseTaxBondsCurrent	74121	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	32458	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	17644	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	126394	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	888929	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	481588	usd
CY2023	skye	Class Of Warrant Or Right Warrants Vested And Outstanding ClassOfWarrantOrRightWarrantsVestedAndOutstanding	3280940	shares
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	59732	usd
CY2022	skye	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	0	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-59729	usd
CY2022	skye	Reclassification Of Derivatives To Equity ReclassificationOfDerivativesToEquity	0	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3	usd
CY2023	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1383285	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	21238	usd
CY2023	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	202254	usd
CY2022	skye	Interest Expense Related Party Stated Rate InterestExpenseRelatedPartyStatedRate	169640	usd
CY2023	skye	Insurance Premium Expense InsurancePremiumExpense	6485	usd
CY2022	skye	Insurance Premium Expense InsurancePremiumExpense	5896	usd
CY2023	skye	Legal Fees Interest Expense LegalFeesInterestExpense	234750	usd
CY2022	skye	Legal Fees Interest Expense LegalFeesInterestExpense	0	usd
CY2023	skye	Bond Premium BondPremium	59929	usd
CY2022	skye	Bond Premium BondPremium	0	usd
CY2023	skye	Premium On Irrevocable Letter Of Credit PremiumOnIrrevocableLetterOfCredit	69861	usd
CY2022	skye	Premium On Irrevocable Letter Of Credit PremiumOnIrrevocableLetterOfCredit	0	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	3100	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	320828	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	488238	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9063	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1359	usd
CY2023	us-gaap	Interest Expense InterestExpense	906270	usd
CY2022	us-gaap	Interest Expense InterestExpense	665133	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6200660	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1270925	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	5000	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	600	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1665083	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5333	usd
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5333	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	33131	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	987510	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	608199	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3955054	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P7Y2M8D
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37644784	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37644784	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7006038	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.37
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-19481602	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19481602	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2221080	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.77
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5600988	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	989826	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-25799330	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18801570	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-11841854	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-673291	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37641184	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19474861	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3600	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6741	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3600	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6741	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40900348	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	30648168	usd
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	17157029	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	8824896	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	1320526	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	1306098	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	663197	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	286452	usd
CY2023Q4	skye	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	225678	usd
CY2022Q4	skye	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	216077	usd
CY2023Q4	skye	Deferred Tax Assets Research And Development Credits DeferredTaxAssetsResearchAndDevelopmentCredits	3694501	usd
CY2022Q4	skye	Deferred Tax Assets Research And Development Credits DeferredTaxAssetsResearchAndDevelopmentCredits	1199256	usd
CY2023Q4	skye	Deferred Tax Assets Sr And Ed Credits DeferredTaxAssetsSRAndEDCredits	1835326	usd
CY2022Q4	skye	Deferred Tax Assets Sr And Ed Credits DeferredTaxAssetsSRAndEDCredits	1000777	usd
CY2023Q4	skye	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	51086	usd
CY2022Q4	skye	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	16565	usd
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	777	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	756	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	663067	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	473429	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66511533	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43972473	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66461557	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43957489	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	49976	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14984	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	49976	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	14984	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	49976	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14984	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7904649	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4089720	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-847810	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-749744	usd
CY2023	skye	Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant	0	usd
CY2022	skye	Effective Income Tax Rate Reconciliation Nondeductible Expense Change In Fair Value Of Warrant EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInFairValueOfWarrant	-76672	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3167507	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-892837	usd
CY2023	skye	Effective Income Tax Rate Reconciliation Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsAmount	1008482	usd
CY2022	skye	Effective Income Tax Rate Reconciliation Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsAmount	884911	usd
CY2023	skye	Effective Income Tax Rate Reconciliation Change In Derivative Amount EffectiveIncomeTaxRateReconciliationChangeInDerivativeAmount	0	usd
CY2022	skye	Effective Income Tax Rate Reconciliation Change In Derivative Amount EffectiveIncomeTaxRateReconciliationChangeInDerivativeAmount	4974768	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	0	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	35624	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	100958	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	69754	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	315498	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	281709	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	6042	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-3568	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1918633	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	14934	usd
CY2023	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	2269297	usd
CY2022	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	0	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	4455195	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-17293	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	121000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3600	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6741	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	22504068	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2872020	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1784626	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1243191	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1087413	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2316932	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	19	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6432143	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2872020	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q1	skye	Related Party Transaction Compensation Agreement Termination Advance Notice Duration RelatedPartyTransactionCompensationAgreementTerminationAdvanceNoticeDuration	P15D
CY2021Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2021Q3	skye	Lessee Operating Lease Abatement Term LesseeOperatingLeaseAbatementTerm	P2M
CY2021Q3	skye	Lessee Operating Lease Initial Monthly Rent LesseeOperatingLeaseInitialMonthlyRent	8067	usd
CY2021Q3	skye	Lessee Operating Lease Annual Rent Increase Percent LesseeOperatingLeaseAnnualRentIncreasePercent	0.03
CY2023Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P36M
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	90701	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.15
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	103216	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	106313	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	90798	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	300327	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	57059	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	243268	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	72038	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	78700	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	171230	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	243268	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	78700	usd
CY2023Q4	skye	Loss Contingency Net Cash Received To Cover Legal Expenses LossContingencyNetCashReceivedToCoverLegalExpenses	5000000	usd

Files In Submission

Name	View Source	Status
0001516551-24-000048-index-headers.html	Edgar Link	pending
0001516551-24-000048-index.html	Edgar Link	pending
0001516551-24-000048.txt	Edgar Link	pending
0001516551-24-000048-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skye-20231231.htm	Edgar Link	pending
skye-20231231.xsd	Edgar Link	pending
skye-20231231xex311.htm	Edgar Link	pending
skye-20231231xex312.htm	Edgar Link	pending
skye-20231231xex321.htm	Edgar Link	pending
skye-20231231xex322.htm	Edgar Link	pending
skye-20231231_g1.jpg	Edgar Link	pending
skye-ararticlesofincorpora.htm	Edgar Link	pending
skye-compensationrecoupmen.htm	Edgar Link	pending
skye-consentofmarcumllpxex.htm	Edgar Link	pending
skye-descriptionofsecuriti.htm	Edgar Link	pending
skye-planofmergerandreorga.htm	Edgar Link	pending
skye-subsidiariesoftheregi.htm	Edgar Link	pending
skye-20231231_def.xml	Edgar Link	unprocessable
skye-20231231_lab.xml	Edgar Link	unprocessable
skye-20231231_pre.xml	Edgar Link	unprocessable
skye-20231231_htm.xml	Edgar Link	completed
skye-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKYE
Skye Bioscience, Inc. Stock $skye

2024 Q1 Form 10-K Financial Statement

#000151655124000048 Filed on March 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE Skye Bioscience, Inc. Stock $skye

2024 Q1 Form 10-K Financial Statement

#000151655124000048 Filed on March 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKYE
Skye Bioscience, Inc. Stock $skye